Abstract
Targeted therapy is considered as a significant improvement of the thyroid cancer therapy. Benefit from the sorafenib, lenvatinib, vandetanib and cabozantinib treatment is nowadays available for the patients with thyroid cancer refractory to radioactive iodine.
Prior to initiation of tyrosine kinase inhibitors therapy, it is important to consider size of the lesions and their growth rate. An important part of the treatment of patients with refractory thyroid cancer is watchful waiting.